Sunday, January 26, 2014 6:19:24 AM
Robert Gorter speaks about the cancer treatment protocol at MCC in The Gary Null Show and about the immune restoration importance in the cancer treatment. Notice DCVax is his dendritic cell therapy
http://medical-center-cologne.com/dendritic-cells/
http://medical-center-cologne.com/what-we-treat/
Experts expect that within a few years, dendritic cells will become a part of the standard treatment of various forms of cancer. Dr. Gorter states that:
“The Gorter Model promotes especially immune, nontoxic cancer therapies, where the dendritic cells play the crucial role. I think quickly now the application and the treatment with dendritic cells as a component of the immune therapy is the future, I believe almost everybody will agree. So I think with the Gorter Model, which we started about 30 years ago, we will help also mainstream medical doctors to implement and understand the function of immune, nontoxic cancer therapy.”
Conditions that have been successfully treated with the Gorter Model include all metastasized solid tumors, such as breast, prostate, lung, liver, brain, colo-rectal, kidney and bone cancer.
More than 4000 patients were treated at Medical Center Cologne so far.? 96% of the patients who have sought care at the MCC have come to the center with an initial diagnosis of terminal disease with no remaining therapeutic options. However, they frequently experience partial remission and stabilize for several years with a very positive quality of life and numerous patients experience even sustained and complete remission.
The treatment implies hope, although not all patients improve. However, the cancer therapy offered at the Medical Center Cologne is nontoxic and does not debilitate patients. Even patients with Stage IV cancer often report that they feel a certain sense of vitality and are able to maintain or improve their quality of life throughout much of the course of their illness.
Patient's Experience at MCC
To date 48% of all patients with Glioblastoma multiforme Stage IV went in complete and long-lasting remission. This is remarkable, given that statistics from the medical literature indicate that with standard treatment, about 72% of all patients who have been diagnosed with Glioblastoma multiforme Stage IV die within the first year of diagnosis and only 1% survive three years.
These outcomes reflect the positive survival rates frequently seen in the patients at the Medical Center Cologne. Dendritic cell therapy has been an integral aspect of Dr. Gorter’s treatment for more than 10 years. This work has pioneered a very moderate approach to hyperthermia and immunotherapy, developing safe, effective protocols that are now being validated in the peer-reviewed medical literature. Today, research centers worldwide are studying dendritic cell therapy, which continues to emerge “as a potentially powerful, non-toxic and broadly useful vaccination strategy for cancer patients.”
To restore the immune system of cancer patiets, the Gorter Model includes a regimen of hyperthermia modelities, dendritic cell therapy, mistletoe injections, Vitamin C, nutrients and antioxidant therapies and life style changes. His recent book “Fighting Cancer: A Nontoxic Approach to Treatment” , co-written with Dr. Erik Peper, who was treated with the Gorter Model, is a thorough review of this novel cancer treatment and provides insights on adopting life style practices to improve and maintain high immune function. Dr. Erik Peper is an internationally recognized expert in holistic health, stress management and biofeedback.
He has written many health articles for publications such as Men’s Health, Shape, Women’s Health, and the San Francisco Chronicle. Dr. Peper was diagnosed with melanoma and after conventional treatment and recurrence, was treated by Dr. Gorter with the Gorter Model.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM